Adaptive deep brain stimulation

Also known as Adaptive DBS, aDBS, Closed-loop deep brain stimulation, Deep brain stimulation (DBS)

Deep brain stimulation (DBS) uses implanted electrodes to deliver electrical pulses to deep brain areas and is established for Parkinson's disease and other movement disorders. Adaptive DBS reads a brain signal and changes stimulation as that signal changes; the FDA approved a Medtronic adaptive system for Parkinson's disease in early 2025, according to the manufacturer, while its use in depression remains experimental.

CommercialDemonstratedReviewed 21 Oct 2026
AI illustration · Illustrative scene, not a photograph of the specific device or experiment.

In plain language

Deep brain stimulation (DBS) uses a thin wire electrode placed in a small target area deep in the brain. An implanted pulse generator sends small, steady electrical pulses through the electrode, which can calm circuits that have become overactive, such as those involved in the movement problems of Parkinson's disease. The settings can be adjusted from outside the body after surgery.

Standard DBS runs at the same settings all the time, whether or not the brain needs help at that moment. Adaptive DBS, also called closed-loop DBS, reads a brain signal through the implanted electrode and turns stimulation up or down as that signal changes. In Parkinson's disease, the signal is a rhythm in the beta band, which tends to rise when symptoms are worse. The FDA approved Medtronic's BrainSense system for Parkinson's disease in early 2025, according to the manufacturer, which also says it is the only company offering an adaptive DBS system. Early trials suggest it can control symptoms while using less electrical energy, but the evidence base is still small.

Technical explanation

Standard DBS delivers high-frequency pulses, typically around 130 Hz, through contacts in targets such as the subthalamic nucleus or globus pallidus internus. In the 2013 proof-of-principle study by Little and colleagues, stimulation was monopolar, 130 Hz, with 100 microsecond biphasic pulses. Adaptive DBS records local field potentials (LFPs) through the implanted electrode and uses the power in the beta band (13 to 35 Hz in that study) as a control signal. In the on-off approach, stimulation is switched on only when beta power crosses a personalised threshold. In a second approach, stimulation amplitude is scaled in proportion to beta power. ADAPT-PD compared a dual-threshold mode with a single-threshold mode and with continuous DBS, using the Medtronic Percept neurostimulator.

The evidence so far comes from small studies with different designs. Little and colleagues tested adaptive stimulation acutely in eight people with advanced Parkinson's disease and found greater improvement in blinded motor scores than with continuous stimulation, while stimulating for about 44% of the time. A 2024 blinded crossover trial in four men, with six hemispheres tested at home for about one month per condition, used sensing from the subthalamic nucleus or motor cortex and reported less time with the most bothersome symptom. The larger ADAPT-PD trial enrolled 68 people. Its primary target was revised after the planned analysis violated two assumptions of the exact binomial test. On the revised target, 91% of dual-threshold and 79% of single-threshold participants met the goal. The authors describe the P values as nominal. Total electrical energy delivered was about 13% lower with dual-threshold and about 15% lower with single-threshold adaptive stimulation than with continuous DBS.

For depression, the record of DBS is mixed. A 2017 multisite trial of subcallosal cingulate white matter DBS randomised 90 people (60 active, 30 sham) and found no statistically significant difference in response at six months, although the trial reported that safety and feasibility were supported. A 2021 single-patient report described closed-loop stimulation, triggered by a biomarker identified with multi-day intracranial recordings, followed by rapid and sustained improvement in depression. The authors say that result needs testing in broader populations.

What the evidence says

Each statement is typed by the strength of its evidence and linked to the source that supports it.

Demonstrated Shown in a published experiment, test or shipping product.

In 1998, Limousin and colleagues reported that electrical stimulation of the subthalamic nucleus improved off-medication motor and daily-living scores in advanced Parkinson's disease, and that dopaminergic drug doses were reduced.

Sources: [1] · Abstract · medium confidence

In an acute study of eight people with advanced Parkinson's disease, beta-triggered adaptive stimulation improved blinded UPDRS hemibody motor scores by 27.0 ± 7.8% more than continuous stimulation (p = 0.005), while stimulating for about 44% of the time, a 56% reduction compared with continuous stimulation.

Sources: [2] · Results · medium confidence

In a blinded randomised crossover feasibility trial of four men with Parkinson's disease (six hemispheres), home use of adaptive stimulation for about one month per condition reduced the awake time with the most bothersome symptom by 16.3 percentage points on average (p < 0.001), with no significant worsening of the opposite symptom (p = 0.26).

Sources: [3] · Results · medium confidence

In the ADAPT-PD trial, 68 people were enrolled, and 91% of dual-threshold and 79% of single-threshold participants met a post hoc target of no more than a 2-hour daily reduction in on-time without troublesome dyskinesia. The authors describe the P values as nominal, and the target was revised after the planned analysis violated two assumptions of the exact binomial test.

Sources: [4] · Results: primary outcome · medium confidence

In the ADAPT-PD trial, 45 of 52 participants who entered setup (87%) tolerated at least one adaptive mode, and no serious device-related adverse events were reported through long-term follow-up, with an average adaptive stimulation exposure of 17.5 months.

Sources: [4] · Results: tolerability and adverse events · medium confidence

In a 90-person sham-controlled trial of subcallosal cingulate DBS for treatment-resistant depression (60 active, 30 sham), response at six months did not differ significantly between groups (20% vs 17%). Of 28 participants with serious adverse events, eight events in seven participants were judged related to the device or surgery.

Sources: [5] · Abstract

Reported, unverified Stated by a company or team but not independently confirmed.

Medtronic announced that the FDA had approved its BrainSense adaptive DBS system and BrainSense Electrode Identifier for Parkinson's disease in early 2025.

Sources: [7] · Press release text · medium confidence

In one person with treatment-resistant depression, biomarker-triggered closed-loop stimulation was followed by rapid and sustained improvement in depression; the authors say the result needs testing in broader populations.

Sources: [6] · Abstract · medium confidence

Limitations and open problems

  • The adaptive DBS trials are small. Little and colleagues studied eight people acutely and Oehrn and colleagues studied four. Oehrn and colleagues call for larger trials, and Little and colleagues describe their work as a proof of principle.
  • The largest study, ADAPT-PD, was open-label overall, with a single-blind crossover only for participants who tolerated both modes. Its primary target was revised after the planned analysis violated two assumptions of the exact binomial test, so its P values are descriptive, as the authors state.
  • Adaptive control needs a biomarker that tracks symptoms in each person. In the 2024 trial, the full parameterisation of the algorithm remained labour-intensive, and several parameters needed empirical adjustment.
  • The depression evidence is weak. The 2017 sham-controlled trial did not show a statistically significant effect at six months, and the closed-loop depression report describes one person.
  • Surgery and implanted hardware carry risk. In the 2024 trial, a hardware infection required surgical removal and a new device was implanted in one person. In ADAPT-PD, nearly all stimulation-related adverse events resolved during the setup and adjustment phase.
  • Device makers funded or supported some of the key studies. ADAPT-PD was funded by Medtronic, which was involved in its design, conduct and analysis. The 2017 depression trial lists Abbott (formerly St. Jude Medical) as its funder, alongside many other sponsors.

Possible future uses

Speculative

Ideas, not predictions. None of these has been demonstrated.

  • Adaptive DBS for other movement disorders, such as essential tremor or dystonia, if a suitable control signal can be found in each condition.
  • Biomarker-triggered stimulation for treatment-resistant depression, but only if larger trials confirm the single-patient result.
  • Adaptive stimulation for symptoms that come and go over the day, where stimulation could be limited to the periods when it is needed.

Timeline

  1. 15 Oct 1998Limousin and colleagues publish in the New England Journal of Medicine that subthalamic nucleus stimulation improved motor and daily-living scores in advanced Parkinson's disease. Sources: [1]
  2. 12 Jul 2013Little and colleagues publish the first proof-of-principle study of beta-triggered adaptive DBS in Parkinson's disease, in eight people. Sources: [2]
  3. 4 Oct 2021Scangos and colleagues report closed-loop, biomarker-triggered stimulation in one person with treatment-resistant depression. Sources: [6]
  4. 19 Aug 2024Oehrn and colleagues publish a blinded randomised crossover feasibility trial of adaptive versus clinically optimised continuous DBS in four people with Parkinson's disease. Sources: [3]
  5. 3 Mar 2025News-Medical republishes Medtronic's announcement of FDA approval for BrainSense adaptive DBS and the BrainSense Electrode Identifier for Parkinson's disease. The date of the FDA approval itself was not confirmed. Sources: [7]
  6. 22 Sept 2025JAMA Neurology publishes the ADAPT-PD trial, with 68 people enrolled and long-term follow-up in the participants who continued adaptive stimulation. Sources: [4]

Futures this could help bring about

AI illustration
How far away?

Brain implants that stop seizures before they spread

Scaling up · 5 of 8 steps done

AI illustration
How far away?

Treating severe depression in days with brain stimulation

Pilots · 7 of 9 steps done

Related breakthroughs

Glossary

Local field potential (LFP)
A summed electrical signal recorded near a group of neurons, which reflects their combined activity.
Beta band
A range of brain rhythms at roughly 13 to 35 Hz, which tends to be stronger in Parkinson's disease when symptoms are worse.
Closed-loop stimulation
Stimulation that is switched or adjusted automatically in response to a measured brain signal.
Sham stimulation
A control condition in which the device appears to be on, but no therapeutic stimulation is delivered, used to test whether benefits go beyond expectation.

Sources

  1. peer reviewed paper
    Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
    P. Limousin, P. Krack, P. Pollak et al.. New England Journal of Medicine, 15 Oct 1998. DOI: 10.1056/NEJM199810153391603. Accessed 21 Oct 2026.
  2. peer reviewed paper
    Adaptive deep brain stimulation in advanced Parkinson disease
    S. Little, A. Pogosyan, S. Neal et al.. Annals of Neurology, 12 Jul 2013. DOI: 10.1002/ana.23951. Accessed 21 Oct 2026.
  3. peer reviewed paper
    Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial
    Carina R. Oehrn, Stephanie Cernera, Lauren H. Hammer et al.. Nature Medicine, 19 Aug 2024. DOI: 10.1038/s41591-024-03196-z. Accessed 21 Oct 2026.
  4. peer reviewed paper
    Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease: A Nonrandomized Clinical Trial
    Helen M. Bronte-Stewart, Martijn Beudel, Jill L. Ostrem. JAMA Neurology, 22 Sept 2025. DOI: 10.1001/jamaneurol.2025.2781. Accessed 21 Oct 2026.
  5. peer reviewed paper
    Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial
    Paul E. Holtzheimer, Mustafa M. Husain, Sarah H. Lisanby et al.. The Lancet Psychiatry, 4 Oct 2017. DOI: 10.1016/S2215-0366(17)30371-1. Accessed 21 Oct 2026.
  6. peer reviewed paper
    Closed-loop neuromodulation in an individual with treatment-resistant depression
    Katherine W. Scangos, Ankit N. Khambhati, Patrick M. Daly et al.. Nature Medicine, 4 Oct 2021. DOI: 10.1038/s41591-021-01480-w. Accessed 21 Oct 2026.
  7. company announcement
    Medtronic receives FDA approval for BrainSense Adaptive DBS technology
    News-Medical (republishing a Medtronic press release), 3 Mar 2025. Accessed 21 Oct 2026.

Revision history

3 changes since this profile was created.

Changes on 21 Oct 2026
Published on owner instruction (content loop iteration 12 and comparisons batch 3)71040a9
Sources and claims re-checked against originalsfbb434c
Initial profile drafted from primary sources7e66249